Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Ginkgo Bioworks (NYSE: DNA) reported Q1 2026 results and completed the divestiture of its Biosecurity business on April 3, 2026, presenting that unit as discontinued operations.
Key metrics: Q1 revenue $19M (down 49% vs. prior year), GAAP net loss $76M, Adjusted EBITDA $(42)M, and $373M in cash, cash equivalents and marketable securities as of March 31, 2026. Full‑year 2026 cash burn is reaffirmed at $(150)M–$(125)M. Management reiterated focus on scaling its Nebula autonomous lab.
Ginkgo Bioworks (NYSE: DNA) will present first-quarter 2026 results on Thursday, May 7, 2026 at 4:30 p.m. ET with a post-market presentation and Q&A. The live webcast and presentation details will be available on the company investor relations site, and a replay will be posted afterward.
Investors can submit questions in advance via X @Ginkgo with hashtag #GinkgoResults or by email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab on March 2, 2026, a web interface giving researchers remote access to Ginkgo's autonomous lab infrastructure.
Cloud Lab runs on proprietary Reconfigurable Automation Carts (RACs), a fleet of >70 instruments, and an AI agent called EstiMate that assesses protocol compatibility and provides pricing. Ginkgo said it will migrate R&D services onto its Nebula autonomous lab and decommission traditional benches.
Ginkgo Bioworks (NYSE: DNA) reported fourth-quarter 2025 revenue of $33M (down 24% YoY) and GAAP net loss of $81M. Full-year 2025 revenue was $170M (down 25%); GAAP net loss $313M. Adjusted EBITDA improved to $(167)M FY. Cash and marketable securities totaled $423M at year-end. The company announced a planned divestiture of its biosecurity business to a consortium for a minority equity stake, expected to close in H1 2026, and will concentrate investments on building and commercializing autonomous labs. 2026 cash burn guidance: $(150)M–$(125)M.
Ginkgo Bioworks (NYSE: DNA) will present its fourth quarter and full year 2025 results on Thursday, February 26, 2026 at 4:30 p.m. ET. The company said the presentation will include a review of business performance for the period ended December 31, 2025, with a live webcast and later replay available on its investor relations website.
Investors can submit questions in advance via X (hashtag #GinkgoResults) or by emailing investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) and Invaio Sciences announced a collaboration on Feb 18, 2026 to develop microbial manufacturing technology for peptide-based agricultural products.
The program will optimize Ginkgo's engineered strains, fermentation processes, and autonomous lab protocols to enable commercial-scale peptide production that meets growers' cost and usability needs.
Ginkgo Bioworks (NYSE: DNA) and OpenAI report an autonomous laboratory using GPT-5 that cut cell-free protein synthesis reaction costs by 40% versus prior state of the art, producing sfGFP at $422 per gram versus $698 per gram. The system ran 36,000 reaction compositions across six iterative cycles and generated ~150,000 data points.
The collaborative workflow combined GPT-5 reasoning, Ginkgo's cloud laboratory infrastructure, validation via a Pydantic model, and limited human oversight; the AI-improved reagent mix is now commercially available.
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.
Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.
Ginkgo Bioworks (NYSE: DNA) announced a partnership with Carnegie Mellon University on an ARPA-H award for the POSEIDON program (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) dated December 22, 2025. Ginkgo will serve as Commercial Partner while CMU leads the project under principal investigator Rebecca Taylor.
The program aims to develop an orally administered pill with engineered tumor-targeting sensors plus a user-friendly at-home urine screening device. The multidisciplinary team includes researchers from University of Pittsburgh, UMass Amherst, KU Leuven, and corporate partners Velentium Medical, Clinical Research Strategies, and Platypus Bio.
Ginkgo Bioworks (NYSE: DNA) and Agricen announced on Dec 17, 2025 the completion of an initial collaboration to develop and optimize a low-cost, efficient fermentation process for complex bacterial strains used in an Agricen soil amendment product.
The work reduced fermentation time for challenging microbes, freed Agricen to focus on pipeline development, and demonstrated Ginkgo's platform capabilities from small screening through commercial volumes of 20 L to 3,000 L.